Blood neutrophil counts are associated with exacerbation frequency and mortality in COPD.
COPD
Eosinophil
Microbiome
Mortality
Neutrophil
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
01 Jul 2020
01 Jul 2020
Historique:
received:
27
02
2020
accepted:
25
06
2020
entrez:
3
7
2020
pubmed:
3
7
2020
medline:
29
5
2021
Statut:
epublish
Résumé
Identifying patients with COPD at increased risk of poor outcomes is challenging due to disease heterogeneity. Potential biomarkers need to be readily available in real-life clinical practice. Blood eosinophil counts are widely studied but few studies have examined the prognostic value of blood neutrophil counts (BNC). In a large population-based COPD registry in the East of Scotland (TARDIS: Tayside Allergic and Respiratory Disease Information System), BNC were compared to measures of disease severity and mortality for up to 15 years follow-up. Potential mechanisms of disease modification by BNC were explored in a nested microbiome substudy. 178,120 neutrophil counts were obtained from 7220 people (mean follow up 9 years) during stable disease periods. Median BNC was 5200cells/μL (IQR 4000-7000cells/μL). Mortality rates among the 34% of patients with elevated BNCs (defined as 6000-15000cells/μL) at the study start were 80% higher (14.0/100 person years v 7.8/100py, P < 0.001) than those with BNC in the normal range (2000-6000cells/μL). People with elevated BNC were more likely to be classified as GOLD D (46% v 33% P < 0.001), have more exacerbations (mean 2.3 v 1.3/year, P < 0.001), and were more likely to have severe exacerbations (13% vs. 5%, P < 0.001) in the following year. Eosinophil counts were much less predictive of these outcomes. In a sub-cohort (N = 276), patients with elevated BNC had increased relative abundance of Proteobacteria and reduced microbiome diversity. High BNC may provide a useful indicator of risk of exacerbations and mortality in COPD patients.
Sections du résumé
BACKGROUND
BACKGROUND
Identifying patients with COPD at increased risk of poor outcomes is challenging due to disease heterogeneity. Potential biomarkers need to be readily available in real-life clinical practice. Blood eosinophil counts are widely studied but few studies have examined the prognostic value of blood neutrophil counts (BNC).
METHODS
METHODS
In a large population-based COPD registry in the East of Scotland (TARDIS: Tayside Allergic and Respiratory Disease Information System), BNC were compared to measures of disease severity and mortality for up to 15 years follow-up. Potential mechanisms of disease modification by BNC were explored in a nested microbiome substudy.
RESULTS
RESULTS
178,120 neutrophil counts were obtained from 7220 people (mean follow up 9 years) during stable disease periods. Median BNC was 5200cells/μL (IQR 4000-7000cells/μL). Mortality rates among the 34% of patients with elevated BNCs (defined as 6000-15000cells/μL) at the study start were 80% higher (14.0/100 person years v 7.8/100py, P < 0.001) than those with BNC in the normal range (2000-6000cells/μL). People with elevated BNC were more likely to be classified as GOLD D (46% v 33% P < 0.001), have more exacerbations (mean 2.3 v 1.3/year, P < 0.001), and were more likely to have severe exacerbations (13% vs. 5%, P < 0.001) in the following year. Eosinophil counts were much less predictive of these outcomes. In a sub-cohort (N = 276), patients with elevated BNC had increased relative abundance of Proteobacteria and reduced microbiome diversity.
CONCLUSION
CONCLUSIONS
High BNC may provide a useful indicator of risk of exacerbations and mortality in COPD patients.
Identifiants
pubmed: 32611352
doi: 10.1186/s12931-020-01436-7
pii: 10.1186/s12931-020-01436-7
pmc: PMC7329438
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
166Subventions
Organisme : GlaxoSmithKline
ID : TARDIS
Références
Eur Respir J. 2009 May;33(5):1165-85
pubmed: 19407051
Trends Immunol. 2019 Jul;40(7):584-597
pubmed: 31153737
Tob Induc Dis. 2017 May 2;15:25
pubmed: 28469539
Eur Respir J. 2019 May 18;53(5):
pubmed: 30846476
Eur Respir J. 2008 Apr;31(4):869-73
pubmed: 18216052
Am J Respir Cell Mol Biol. 2013 May;48(5):531-9
pubmed: 23328639
Eur Respir J. 2019 Aug 1;54(2):
pubmed: 31073084
Eur Respir J. 2018 Oct 4;52(4):
pubmed: 30139779
Lung. 2016 Dec;194(6):881-887
pubmed: 27530251
Int Immunopharmacol. 2013 Dec;17(4):1211-7
pubmed: 23994347
N Engl J Med. 2010 Sep 16;363(12):1128-38
pubmed: 20843247
J Allergy Clin Immunol. 2018 Jan;141(1):117-127
pubmed: 28506850
Chest. 2011 Jan;139(1):165-73
pubmed: 21208876
COPD. 2012 Apr;9(2):111-20
pubmed: 22458939
Am J Respir Crit Care Med. 2012 Jul 15;186(2):155-61
pubmed: 22561964
Chest. 2008 Sep;134(3):606-612
pubmed: 18779195
PLoS One. 2012;7(6):e38629
pubmed: 22701684
Thorax. 2018 Jun;73(6):510-518
pubmed: 29101284
Proc Am Thorac Soc. 2007 Dec;4(8):626-34
pubmed: 18073394
Eur Respir J. 2015 Sep;46(3):640-50
pubmed: 26160874
Eur Respir J. 2017 Apr 12;49(4):
pubmed: 28404649
Am J Respir Crit Care Med. 2011 May 1;183(9):1176-86
pubmed: 21257786
Thorax. 2010 Oct;65(10):930-6
pubmed: 20627907
Eur Respir Rev. 2018 Feb 7;27(147):
pubmed: 29436405
Science. 2004 Mar 5;303(5663):1532-5
pubmed: 15001782
Eur Respir J. 2007 Mar;29(3):527-34
pubmed: 17107990
PLoS One. 2012;7(5):e37483
pubmed: 22624038
Am J Respir Crit Care Med. 2004 Aug 15;170(4):400-7
pubmed: 15130905
Front Physiol. 2016 Oct 07;7:457
pubmed: 27774071
Thorax. 2018 May;73(5):422-430
pubmed: 29386298
Methods Mol Biol. 2017;1639:67-75
pubmed: 28752447
Eur Respir J. 2008 Oct;32(4):962-9
pubmed: 18579551
Respiration. 2012;83(2):147-58
pubmed: 22094549